trending Market Intelligence /marketintelligence/en/news-insights/trending/4QC3QhkVM1HSI5Sq9-a_GA2 content esgSubNav
In This List

Kitov gets FDA approval to brand osteoarthritis, hypertension drug as Consensi

Video

S&P Capital IQ Pro | Unrivaled Sector Coverage

Video

S&P Capital IQ Pro | Powering Your Edge

Blog

Enterprises are missing out on 24B by not optimizing cloud spending not going multicloud

Blog

Investment Research Analysts Providing Greater Coverage on Inflation


Kitov gets FDA approval to brand osteoarthritis, hypertension drug as Consensi

The U.S. Food and Drug Administration allowed Kitov Pharmaceuticals Holdings Ltd. to use the brand name Consensi for marketing its drug KIT-302.

The permission is subject to receipt of marketing approval from the regulator.

Consensi is a combination of two FDA-approved drugs — Pfizer Inc.'s Celebrex and Norvasc. It is intended to simultaneously treat pain caused by osteoarthritis, as well as hypertension, which is a common side effect of stand-alone drugs that treat osteoarthritis pain.

The expected completion date for FDA's review of the new drug application for Consensi is May 31, 2018.